- SelectQuote, Inc. (SLQT, Financial) expands its innovative medication adherence program to improve health outcomes for polychronic Medicare beneficiaries.
- The new service achieved over 90% adherence during trials, enhancing HEDIS Star ratings in critical health measures.
- SelectRx plans to implement the program across its pharmacy platform by 2026, with further expansions to additional payers this year.
SelectQuote, Inc. (SLQT), a significant player in the Medicare insurance industry, has announced the broader rollout of an innovative service designed to boost medication adherence for Medicare beneficiaries with complex health conditions. The program, which follows a successful trial with a regional health plan, has demonstrated over 90% adherence, significantly improving HEDIS Star ratings in areas such as cholesterol, diabetes, and hypertension.
The company's SelectRx pharmacy has crafted this high-touch service to address medication non-adherence—a key issue that can lead to preventable hospitalizations and additional healthcare costs. This initiative will first focus on high- and medium-risk patients, offering escalations to a clinical pharmacist team when necessary, and will eventually include a program for lower-risk members.
Bob Grant, President of SelectQuote, emphasized the potential for this concierge-like program to substantially improve medication management for Medicare beneficiaries. The service aims to extend SelectQuote's commitment beyond traditional brokerage, providing personalized support that improves quality of life and reduces costly medical incidents.
SelectQuote plans to expand the innovative service to additional payers later this year, with a broader rollout across SelectRx's pharmacy platform anticipated by 2026. This strategic move underscores SelectQuote's mission to enhance patient outcomes while delivering value to patients and payer partners alike.
